Epidermal necrolysis (EN), encompassing the spectrum of Stevens-Johnson syndrome and toxic EN, is a rare, severe cutaneous drug reaction with an estimated mortality in modern cohorts of 15% to 23%.1-3 The rarity of the disease makes rigorous prospective clinical research difficult, highlighting the need for multicenter, multinational collaborations as well as iterative efforts to validate and build on prior work.
Micheletti RG, Noe MH. Improving Outcomes for Patients With Epidermal Necrolysis. JAMA Dermatol. 2020;156(12):1289–1290. doi:10.1001/jamadermatol.2020.3655
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.